Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Atorvastatin
- Indications Coronary disorders; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Organon
- 19 Oct 2006 Status change
- 22 Oct 2005 New trial record.